NCT00378105 · OUTCOME

Percentage of Patients Who Remained in Response for More Than 18 Months

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2026-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Response rate at 18 months

What was measured

Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died.

Groups in this outcome

All Patients

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Patients	66

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
All Patients	68	Not reported	55	79	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
55
upper Limit
79
value
68

denoms

counts
group Id
OG000
value
66
units
Participants

description

Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died.

dispersion Type

95% Confidence Interval

groups

id
OG000
title
All Patients

param Type

NUMBER

reporting Status

POSTED

time Frame

Response rate at 18 months

title

Percentage of Patients Who Remained in Response for More Than 18 Months

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice